Combined antiangiogenic therapy is superior to single inhibitors in a model of renal cell carcinoma.
暂无分享,去创建一个
Georg Bartsch | Shay Soker | Gunter Schuch | C. Bokemeyer | R. Hautmann | S. Soker | G. Bartsch | G. Schuch | Carsten Bokemeyer | Richard Hautmann | Katharina Eggert | K. Eggert
[1] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[2] Shay Soker,et al. Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.
[3] O. Volpert,et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 , 2000, Nature Medicine.
[4] S. Szala,et al. Intra‐tumoral administration of naked plasmid DNA encoding mouse endostatin inhibits renal carcinoma growth , 2001, International journal of cancer.
[5] Nijole Gasiunas,et al. Neuropilin-1 Binds Vascular Endothelial Growth Factor 165, Placenta Growth Factor-2, and Heparin via Its b1b2 Domain* , 2002, The Journal of Biological Chemistry.
[6] S. Soker,et al. In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo. , 2002, Blood.
[7] K. Alitalo,et al. Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. , 2002, Cancer research.
[8] Y. Gho,et al. Endostatin Blocks Vascular Endothelial Growth Factor-mediated Signaling via Direct Interaction with KDR/Flk-1* , 2002, The Journal of Biological Chemistry.
[9] W. Kaelin,et al. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. , 2003, The New England journal of medicine.
[10] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[11] S. Koga,et al. Expression of thrombospondin-derived 4N1K peptide-containing proteins in renal cell carcinoma tissues is associated with a decrease in tumor growth and angiogenesis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] Linhong Li,et al. Rapid, in vivo, evaluation of antiangiogenic and antineoplastic gene products by nonviral transfection of tumor cells , 2004, Cancer Gene Therapy.
[13] M. Atkins,et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] B. Drucker,et al. Renal cell carcinoma: current status and future prospects. , 2005, Cancer treatment reviews.
[15] C. von Kalle,et al. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. , 2005, Blood.
[16] C. Bokemeyer,et al. Antiangiogenic treatment with endostatin inhibits progression of AML in vivo , 2005, Leukemia.
[17] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[18] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[19] H. Pitot,et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results , 2007 .
[20] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.